FDA advisers endorse J&J's canagliflozin for diabetes

01/10/2013 | Wall Street Journal, The

An FDA panel recommended the approval of Johnson & Johnson's Invokana, or canagliflozin to treat type 2 diabetes in a 10-5 vote. Some advisers suggested that patients with impaired kidneys should be told not to take the drug.

View Full Article in:

Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN